Skip to main content
Lilly, Incyte's lupus candidate nabs FDA fast-track status
12/14/2018

The FDA granted fast-track designation to Eli Lilly and Co. and Incyte's baricitinib, which is being developed to treat patients with systemic lupus erythematosus.

Full Story: